Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Mitochondrial dysfunction and oxidative stress are implicated in the neurodegenerative process in Parkinson's disease (PD). Moreover, c-Jun N-terminal kinase (JNK) plays an important role in dopaminergic neuronal death in substantia nigra pars compacta. Tauroursodeoxycholic acid (TUDCA) acts as a mitochondrial stabilizer and anti-apoptotic agent in several models of neurodegenerative diseases. Here, we investigated the role of TUDCA in preventing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration in a mouse model of PD. We evaluated whether TUDCA modulates MPTP-induced degeneration of dopaminergic neurons in the nigrostriatal axis, and if that can be explained by regulation of JNK phosphorylation, reactive oxygen species (ROS) production, glutathione S-transferase (GST) catalytic activation, and Akt signaling, using C57BL/6 glutathione S-transferase pi (GSTP) null mice. TUDCA efficiently protected against MPTP-induced dopaminergic degeneration. We have previously demonstrated that exacerbated JNK activation in GSTP null mice resulted in increased susceptibility to MPTP neurotoxicity. Interestingly, pre-treatment with TUDCA prevented MPTP-induced JNK phosphorylation in mouse midbrain and striatum. Moreover, the anti-oxidative role of TUDCA was demonstrated in vivo by impairment of ROS production in the presence of MPTP. Finally, results herein suggest that the survival pathway activated by TUDCA involves Akt signaling, including downstream Bad phosph…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tauroursodeoxycholic acid (TUDCA), an endogenous bile acid, has a neuroprotective effect in models of Parkinson's disease.[214][215][216]”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [214]
In the citing paper
“Multiple in vivo studies have demonstrated the neuroprotective effects of UDCA and TUDCA in counteracting mitochondrial dysfunction, oxidative stress, and neuroinflammation within PD mouse models.386–392”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [388]
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115 · cited 2×
“This kinase may be activated by phosphorylation within the carboxy terminus at Ser 473 [40].”
BackgroundMethodAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689 · cited 1×
“Active Akt directly phosphorylates Bad on Ser 136, triggering the release of Bad from its mitochondrial targets [53].”
BackgroundDauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · cited 2×
“The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin constitutes the best-characterized toxin paradigm for PD, faithfully replicating most of its clinical and pathological hallmarks in humans and animal models [1].”
BackgroundInterleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797 · cited 1×
“Pro-apoptotic Bad forms heterodimers with the anti-apoptotic proteins Bcl-xL or Bcl-2, antagonizing their anti-apoptotic activity [52].”
BackgroundMolecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663 · cited 1×
“Several possible mechanisms leading to dopaminergic neurodegeneration in PD have been proposed, including mitochondrial complex I dysfunction, impairment of ATP production, oxidative stress, neuroinflammation, and aberrant proteolytic degradation [3].”
BackgroundNF-κB is a target of AKT in anti-apoptotic PDGF signalling
Romashkova, J. A., & Makarov, S. S. (1999) · Nature · doi:10.1038/43474 · Cited by 1,517
Regulation of JNK signaling by GSTp
Adler, V. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1321 · Cited by 1,116 · cited 1×
“In GSTP null mice, the constitutive activation of JNK pathway is higher [47, 48].”
BackgroundSelf-citationInduction of NF-κB by the Akt/PKB kinase
Kane, L. P., Shapiro, V. S., Stokoe, D., & Weiss, A. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80265-6 · Cited by 846
Rodrigues, C. M., Fan, G., Ma, X., Kren, B. T., & Steer, C. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1325 · Cited by 520 · cited 1×
“drial membrane potential, and prevent cytochrome c release, Bax translocation, caspase activation, and apoptosis in hepatocytes exposed to apoptotic stimuli [18, 22, 23].”
BackgroundSelf-citationMorrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.314 · Cited by 510 · cited 1×
“In PD, approximately 50–70% of the dopaminergic neurons are already lost at the time of clinical diagnosis [55].”
BackgroundHunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., Rakic, P., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307453101 · Cited by 426 · cited 2×
“Indeed, increased levels of phosphorylated JNK and its downstream target c-Jun were found in brains from PD patients [10, 11], and JNK is active in degenerating dopaminergic neurons in the substantia nigra pars compacta (SNpc) of MPTP-treated mice [11–14].”
BackgroundUrsodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 411 · cited 2×
“Moreover, UDCA is FDAapproved to treat liver diseases [17] and its administration is also safe and well tolerated in patients with amyotrophic lateral sclerosis [54].”
BackgroundNeuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Lee Mosley, R., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 387
Increased skin tumorigenesis in mice lacking pi class glutathione S -transferases
Henderson, C. J., Smith, A. G., Ure, J., Brown, K., Bacon, E. J., & Wolf, C. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5275 · Cited by 376 · cited 1×
“The work we report here his based on this double-knockout line since in the mouse both Gstp genes (Gstp1 and Gstp2) are arranged in tandem on chromosome 1 and were deleted by homologous recombination [35].”
BackgroundSelf-citationRodrigues, C. M. P., Fan, G., Wong, P. Y., Kren, B. T., & Steer, C. J. (1998) · Molecular Medicine · doi:10.1007/bf03401914 · Cited by 334 · cited 2×
“TUDCA is an effective inhibitor of apoptosis through different cellular mechanisms, namely by interfering with the mitochondrial pathway of cell death [18], as well as with”
BackgroundSelf-citationParkinson's disease, pesticides, and glutathione transferase polymorphisms
Menegon, A., Board, P. G., Blackburn, A. C., Mellick, G. D., & Couteur, D. G. L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03453-9 · Cited by 314 · cited 1×
“Moreover, GSTP1 polymorphisms are associated with increased risk of incidence for PD, indicating a neuroprotective role for native GSTP1 [43, 44].”
BackgroundOxidative and Inflammatory Pathways in Parkinson’s Disease
Miller, R. L., James-Kracke, M., Sun, G. Y., & Sun, A. Y. (2009) · Neurochemical Research · doi:10.1007/s11064-008-9656-2 · Cited by 306
Keene, C. D., Rodrigues, C. M. P., Eich, T., Chhabra, M. S., Steer, C. J., & Low, W. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162362299 · Cited by 306 · cited 2×
“evidence also point to an important protective role of TUDCA in both in vitro and in vivo models of neurologic disorders, such as Huntington’s disease [24, 25], Alzheimer’s disease [26–30], and stroke [31, 32].”
BackgroundSelf-citationOxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300 · cited 1×
“leading to irreversible damage in DNA, proteins, and lipids, as well as to dysfunction of the energy metabolism [45].”
BackgroundRodrigues, C. M., Ma, X., Linehan-Stieers, C., Fan, G., Kren, B. T., & Steer, C. J. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400560 · Cited by 260 · cited 1×
“drial membrane potential, and prevent cytochrome c release, Bax translocation, caspase activation, and apoptosis in hepatocytes exposed to apoptotic stimuli [18, 22, 23].”
BackgroundSelf-citationVed, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M. P., Alfonso, A., Steer, C., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505910200 · Cited by 255 · cited 1×
“Additionally, TUDCA was demonstrated to have a beneficial role in survival and function of nigral transplant in a rat model of PD [33] and also to partially rescue mitochondrial dysfunction in genetic PD models in Caenorhabditis elegans [34].”
BackgroundSelf-citationRapid ATP Loss Caused by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mouse Brain
Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W., & Di Monte, D. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02134.x · Cited by 241 · cited 1×
“MPTP and its toxic metabolite, 1-methyl-4-phenylpyridinium (MPP), used extensively in in vitro and in vivo models of PD, cause degeneration of nigrostriatal dopaminergic neurons mediated via ROS generation, mitochondrial membrane potential depolarization, and activation of cell death signaling pathways [1, 2, 7, 8].”
BackgroundSaporito, M. S., Thomas, B. A., & Scott, R. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751200.x · Cited by 232
Rodrigues, C. M. P., Solá, S., Nan, Z., Castro, R. E., Ribeiro, P. S., Low, W. C., & Steer, C. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031632100 · Cited by 210 · cited 2×
“evidence also point to an important protective role of TUDCA in both in vitro and in vivo models of neurologic disorders, such as Huntington’s disease [24, 25], Alzheimer’s disease [26–30], and stroke [31, 32].”
BackgroundSelf-citationNunes, A. F., Amaral, J. D., Lo, A. C., Fonseca, M. B., Viana, R. J. S., Callaerts-Vegh, Z., D’Hooge, R., & Rodrigues, C. M. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8256-y · Cited by 192
Self-citationAnimal models of Parkinson's disease
Jackson-Lewis, V., Blesa, J., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70057-8 · Cited by 191
Wang, W., Shi, L., Xie, Y., Ma, C., Li, W., Su, X., Huang, S., Chen, R., Zhu, Z., Mao, Z., et al. (2004) · Neuroscience Research · doi:10.1016/j.neures.2003.10.012 · Cited by 160 · cited 1×
“In accordance with this, JNK null mice are resistant to MPTP neurotoxicity, and selective JNK inhibitors were also shown to protect against MPTP-induced neurodegeneration in the nigrostriatal dopaminergic neurons in vivo [11, 15, 16].”
BackgroundNeuroprotection by a Bile Acid in an Acute Stroke Model in the Rat
Rodrigues, C. M. P., Spellman, S. R., Solá, S., Grande, A. W., Linehan-Stieers, C., Low, W. C., & Steer, C. J. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200204000-00010 · Cited by 160 · cited 2×
“evidence also point to an important protective role of TUDCA in both in vitro and in vivo models of neurologic disorders, such as Huntington’s disease [24, 25], Alzheimer’s disease [26–30], and stroke [31, 32].”
BackgroundSelf-citationElsby, R., Kitteringham, N. R., Goldring, C. E., Lovatt, C. A., Chamberlain, M., Henderson, C. J., Wolf, C. R., & Park, B. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301211200 · Cited by 159
Self-citationKeene, C. D., Rodrigues, C. M. P., Eich, T., Linehan-Stieers, C., Abt, A., Kren, B. T., Steer, C. J., & Low, W. C. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7755 · Cited by 144 · cited 2×
“administration of MPTP at a single dose (40 mg/kg body weight) on day 3, 6 h after the last TUDCA injection [24, 36].”
BackgroundMethodSelf-citationStetler, R. A., Cao, G., Gao, Y., Zhang, F., Wang, S., Weng, Z., Vosler, P., Zhang, L., Signore, A., Graham, S. H., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4407-08.2008 · Cited by 135 · cited 2×
“One such ROS-activated protein is heat shock transcription factor 1 (HSF1), which binds to heat shock elements in the promoter of heat shock genes, and is responsible for the transcriptional regulation of Hsp genes, namely Hsp27 [37, 46].”
BackgroundMitochondrial alterations in Parkinson’s disease: new clues
Vila, M., Ramonet, D., & Perier, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05604.x · Cited by 131
Parry, G. J., Rodrigues, C. M. P., Aranha, M. M., Hilbert, S. J., Davey, C., Kelkar, P., Low, W. C., & Steer, C. J. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181c47569 · Cited by 128 · cited 1×
“Moreover, UDCA is FDAapproved to treat liver diseases [17] and its administration is also safe and well tolerated in patients with amyotrophic lateral sclerosis [54].”
BackgroundSelf-citationApoptotic molecules and MPTP-induced cell death
Nicotra, A., & Parvez, S. H. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00213-1 · Cited by 125 · cited 1×
“MPTP and its toxic metabolite, 1-methyl-4-phenylpyridinium (MPP), used extensively in in vitro and in vivo models of PD, cause degeneration of nigrostriatal dopaminergic neurons mediated via ROS generation, mitochondrial membrane potential depolarization, and activation of cell death signaling pathways [1, 2, 7, 8].”
BackgroundSolá, S., Castro, R. E., Laires, P. A., Steer, C. J., & Rodrigues, C. M. P. (2003) · Molecular Medicine · doi:10.2119/2003-00042.rodrigues · Cited by 118 · cited 2×
“We have already shown that TUDCA activates Akt signaling using other experimental paradigms [26, 39].”
BackgroundSelf-citationDuan, W.-M., Rodrigures, C. M. P., Zhao, L.-R., Steer, C. J., & Low, W. C. (2002) · Cell Transplantation · doi:10.3727/096020198389960 · Cited by 108 · cited 1×
“Additionally, TUDCA was demonstrated to have a beneficial role in survival and function of nigral transplant in a rat model of PD [33] and also to partially rescue mitochondrial dysfunction in genetic PD models in Caenorhabditis elegans [34].”
BackgroundTargeting the JNK Signaling Pathway for Stroke and Parkinsons Diseases Therapy
Kuan, C.-Y., & Burke, R. (2005) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007053005145 · Cited by 100 · cited 1×
“The c-Jun N-terminal kinase (JNK) pathway constitutes a central stress activated response implicated in the pathogenesis of PD [9].”
BackgroundWang, X.-T., Pei, D., Xu, J., Guan, Q., Sun, Y., Liu, X., & Zhang, G. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.005 · Cited by 96 · cited 1×
“For example, pAkt enhances cell survival by inhibiting the function of proapoptotic proteins, namely the Bcl-2 family member Bad [39, 51].”
BackgroundThe Role of c‐Jun N‐Terminal Kinase (JNK) in Parkinson's Disease
Peng, J., & Andersen, J. (2003) · IUBMB Life · doi:10.1080/1521654031000121666 · Cited by 91 · cited 1×
“Indeed, increased levels of phosphorylated JNK and its downstream target c-Jun were found in brains from PD patients [10, 11], and JNK is active in degenerating dopaminergic neurons in the substantia nigra pars compacta (SNpc) of MPTP-treated mice [11–14].”
BackgroundHSP27 and cell survival in neurones
Latchman, D. S. (2004) · International Journal of Hyperthermia · doi:10.1080/02656730400023664 · Cited by 87 · cited 1×
“Hsp27 has been described as a potent neuroprotective factor against several neuronal insults [38].”
BackgroundRamalho, R. M., Ribeiro, P. S., Solá, S., Castro, R. E., Steer, C. J., & Rodrigues, C. M. P. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02517.x · Cited by 82 · cited 1×
“targets upstream of mitochondria, including cell cycle related proteins E2F-1 and p53 [19] and endoplasmic reticulum stress [20].”
BackgroundSelf-citationRamalho, R. M., Borralho, P. M., Castro, R. E., Solá, S., Steer, C. J., & Rodrigues, C. M. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04007.x · Cited by 71
Self-citationCastro, R. E., Solá, S., Ramalho, R. M., Steer, C. J., & Rodrigues, C. M. P. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.070532 · Cited by 66 · cited 3×
“For example, pAkt enhances cell survival by inhibiting the function of proapoptotic proteins, namely the Bcl-2 family member Bad [39, 51].”
BackgroundSelf-citationMouse HSF1 Disruption Perturbs Redox State and Increases Mitochondrial Oxidative Stress in Kidney
Yan, L.-J., Rajasekaran, N. S., Sathyanarayanan, S., & Benjamin, I. J. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.465 · Cited by 65 · cited 1×
“glutathione, which decreases the intracellular ROS levels [49], therefore inhibiting the stimulus eliciting JNK activation.”
BackgroundTauroursodeoxycholic acid prevents E22Q Alzheimer’s Aβ toxicity in human cerebral endothelial cells
Viana, R. J. S., Nunes, A. F., Castro, R. E., Ramalho, R. M., Meyerson, J., Fossati, S., Ghiso, J., Rostagno, A., & Rodrigues, C. M. P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8746-x · Cited by 64
Self-citationSolá, S., Amaral, J. D., Borralho, P. M., Ramalho, R. M., Castro, R. E., Aranha, M. M., Steer, C. J., & Rodrigues, C. M. P. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0063 · Cited by 60
Self-citationCastro‐Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., & Gama, M. J. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8266-9 · Cited by 56 · cited 5×
“However, we have recently shown that when GSTP null mice are treated with MPTP, the levels of p-JNK are only transiently increased [14], indicating that in the absence of GSTP other cellular repressors must compensate for the lack of this important JNK regulator.”
BackgroundResultInfluentialSelf-citationPan, J., Qian, J., Zhang, Y., Ma, J., Wang, G., Xiao, Q., Chen, S., & Ding, J. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.124 · Cited by 42 · cited 1×
“In accordance with this, JNK null mice are resistant to MPTP neurotoxicity, and selective JNK inhibitors were also shown to protect against MPTP-induced neurodegeneration in the nigrostriatal dopaminergic neurons in vivo [11, 15, 16].”
BackgroundFLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP+
Kong, X., Zhang, D., Qian, C., Liu, G.-T., & Bao, X.-Q. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.093 · Cited by 39 · cited 3×
“In fact, it has been previously shown that synthesis of Hsp27 in SH-SY5Y cells after MPP exposure was increased owing to a self-protection mechanism [37].”
BackgroundCastro‐Caldas, M., Carvalho, A. N., Peixeiro, I., Rodrigues, E., Lechner, M. C., & Gama, M. J. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9141-z · Cited by 38 · cited 4×
“administration of MPTP at a single dose (40 mg/kg body weight) on day 3, 6 h after the last TUDCA injection [24, 36].”
BackgroundMethodInfluentialSelf-citationVilar, R., Coelho, H. G. B., Rodrigues, E., Gama, M. J., Rivera, I. A., Taioli, E., & Lechner, M. C. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01590.x · Cited by 37 · cited 1×
“Moreover, GSTP1 polymorphisms are associated with increased risk of incidence for PD, indicating a neuroprotective role for native GSTP1 [43, 44].”
BackgroundSelf-citationNishi, K. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00862-7 · Cited by 33
Viana, R. J. S., Ramalho, R. M., Nunes, A. F., Steer, C. J., & Rodrigues, C. M. P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100909 · Cited by 27 · cited 1×
“Importantly, TUDCA was also shown to efficiently modulate the activation of the JNK pathway in Aβtreated PC12 neuronal cells [21].”
BackgroundSelf-citationAmyloid-β Peptide-Induced Secretion of Endoplasmic Reticulum Chaperone Glycoprotein GRP94
Viana, R. J. S., Steer, C. J., & Rodrigues, C. M. P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-100395 · Cited by 18
Self-citationKitani, K., Kanai, S., Sato, Y., Ohta, M., & Nokubo, M. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00500-1 · Cited by 10 · cited 1×
“UDCAwas shown to increase liver GST catalytic activity in response to toxic insults [50].”
Background
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916945 · Cited by 536
Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
Hamamah, S., Aghazarian, A., Nazaryan, A., Hajnal, A., & Covasa, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020436 · Cited by 307
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
The therapeutic potential of chemical chaperones in protein folding diseases
Cortez, L., & Sim, V. (2014) · Prion · doi:10.4161/pri.28938 · Cited by 254
“Additionally, intraperitoneal injection of TUDCA in mouse model of PD prevented dopaminergic cell death through the activation of pro-survival pathways.(59) Future therapeutic potential Bile acids, in particular TUDCA and UDCA, have received increasing attention as potential treatments for neurodegenerative conditions…”
Background
Metadata
- Authors
- Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M. P., & Gama, M. J.
- Affiliations
- University of Lisbon (PT)
- Ninewells Hospital (GB)
- Corresponding author
- Gama, M. J.
- Venue
- Molecular Neurobiology
- Published
- 2012-07-08
- Volume
- 46
- Issue
- 2
- Pages
- 475-486
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2034424279
- Cited by
- 156
- References
- 56
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 10 · 2023: 19 · 2022: 15 · 2021: 13 · 2020: 13 · 2019: 13 · 2018: 10 · 2017: 10 · 2016: 12 · 2015: 6 · 2014: 9 · 2013: 5
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Funders
- Cancer Research UK (10822)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Keywords
- tauroursodeoxycholic acid, Parkinson's disease, MPTP-induced neurotoxicity, dopaminergic neuron loss, substantia nigra pars compacta, c-Jun N-terminal kinase, JNK phosphorylation, oxidative stress, reactive oxygen species, glutathione S-transferase pi, Akt signaling, Bad phosphorylation, NF-κB, neuroprotection, mitochondrial dysfunction, nigrostriatal pathway
- MeSH terms
- NF-KappaB Inhibitor alpha, Animals, Disease Models, Animal, Mice, Inbred C57BL, Nerve Degeneration, Parkinson Disease, Phosphorylation, Taurochenodeoxycholic Acid, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, NF-kappa B, Cell Death, Reactive Oxygen Species, Mice, Knockout, Neuroprotective Agents, I-kappa B Proteins, Intracellular Space, JNK Mitogen-Activated Protein Kinases, bcl-Associated Death Protein, Mice, HSP27 Heat-Shock Proteins, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.